| StockFetcher Forums · General Discussion · What do you think of GNBT? | << 1 2 3 4 >>Post Follow-up |
| TheRumpledOne 6,411 posts msg #42564 - Ignore TheRumpledOne modified |
3/27/2006 3:19:37 PM http://www.smallcapcenter.com/story.asp?mysection=headlines&mypage=newsalerts.asp&ticker=GNBT&NewsFeed=1&storyid=3837716 |
| gobi 9 posts msg #42570 - Ignore gobi |
3/27/2006 8:51:18 PM Thanks for clarifying this, TRO. |
| shaikhhali 42 posts msg #42733 - Ignore shaikhhali |
4/4/2006 11:55:47 AM GNBT is below the 50%(2.45) from its peak value, is this a good ponit to buy? |
| TheRumpledOne 6,411 posts msg #42734 - Ignore TheRumpledOne |
4/4/2006 1:20:24 PM Market Ratings From StockPickReport via COMTEX April 4, 2006 SHREVEPORT, La., Apr 4, 2006 (PRIMEZONE via COMTEX) -- StockPickReport.Com (IARD #119079, www.stockpickreport.com), rates Generex Biotechnology (Nasdaq:GNBT), Avanex (Nasdaq:AVNX), General Motors (NYSE:GM), and Comverse Technology (NYSE:GM). StockPickReport.com provides unbiased stock ratings from registered investment advisors. StockPickReport offers subscription services for Swing traders, Day traders and Penny Stock Traders. StockPickReport.com issues daily market commentary and features a member's area with detailed information on over 12,000 stocks. Important Stock Rating Changes: Generex Biotechnology Corporation (Nasdaq:GNBT) -- SELL www.stockpickreport.com/abrating.php?sym=GNBT Avanex Corporation (Nasdaq:AVNX) -- BUY www.stockpickreport.com/abrating.php?sym=AVNX General Motors Corporation (NYSE:GM) -- SELL www.stockpickreport.com/abrating.php?sym=GM Comverse Technology Inc (Nasdaq:CMVT) -- STRONG BUY www.stockpickreport.com/abrating.php?sym=CMVT StockPickReport Commentary -- April 04, 2006 The market is a "mixed bag." I can see where there may be upside over the next week or so. But, on a longer term basis -- and this may shock you -- the market has not displayed the classic "oversold" indications I'd like to see before I make a "long term" commitment. Even the downslide of the 2000 to 2002 did not achieve the "pure" oversold conditions on RSI. My gut reaction to the market is that there will be some upside but the pressure to move south will hold back anything significant. I gotta tell you, though, that I am not fond of trading the market under current conditions. No clear markers for an upswing and some point down. I can see the stock going either way, and that's not how I like to trade. I like to get as many indicators on my side as I can. You can see videos on my trades at www.donharrold.net StockPickReport Disclaimer: www.stockpickreport.com/disclaimer.html This news release was distributed by PrimeZone, www.primezone.com SOURCE: StockPickReport.com INVESTMENT OPINION StockPickReport info@stockpickreport.com www.stockpickreport.com (C) 2006 PRIMEZONE, All rights reserved. ********************************************************************** As of Friday, 03-31-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated an UPTREND on 06-02-2005 for AVNX @ $1.18. As of Friday, 03-31-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated a DOWNTREND on 03-14-2006 for CMVT @ $25.70. As of Friday, 03-31-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated an UPTREND on 03-22-2006 for GM @ $22.37. (C) 2006 Comtex News Network, Inc. All rights reserved. |
| shaikhhali 42 posts msg #42736 - Ignore shaikhhali |
4/4/2006 4:19:49 PM Thanks TRO |
| TheRumpledOne 6,411 posts msg #42778 - Ignore TheRumpledOne |
4/6/2006 2:16:57 PM marketgainer.com: Reporting on Generex Biotechnology Corporation via COMTEX April 6, 2006 Apr 06, 2006 (M2 PRESSWIRE via COMTEX News Network) -- Market Gainer is quickly emerging as a one stop shop for the elite information regarding small cap opportunities in the Canadian and American exchanges. Today's activity on the Nasdaq has brought Nanoscience Technologies Incorporated (NASDAQ:GNBT) to the attention of our research team. Visit our website to obtain more information on this company and others like it. Our research team strives to bring undervalued opportunities to the attention of avid traders, in order to create an international community of investors. Generex Biotechnology Corporation engages in the research and development of drug delivery systems and technology. It develops a proprietary platform technology for the delivery of drugs into the human body through the oral cavity. Nanoscience Technologies Incorporated appears to be having a strong day, inching up towards its 52 week high, currently trading at $2.76. The market sentiment is up 5%,for this undervalued small cap company. Well over 300 thousand shares changed at the time of publication. One thing to consider is Generex Biotechnology Corporation has not released any sort of corporate development to justify the current levels. This is not to say the adjustment is not relative, it may just be a sign of things to come. Needles to say, MG will keep a close eye on Generex Biotechnology Corporation for the weeks to come. The information provided is brief and informative and has been brought to you from the Market Gainer research team. This should not be construed as a buy, sell, or hold recommendation. To view past corporate development and current opinions from other investors, visit Market Gainer where you can interact with international investors about companies in this sector. Visit www.marketgainer.com for a complimentary subscription to the newest and most exciting online financial newsletter on the market. This article is available for viewing in the featured articles section on our website. No Credit Card information needed. New to the Market Gainer's website is our very own in-site blog, offering our subscribers the opportunity to communicate with fellow investors without all the spam found in other investment blogs. Click on talking stocks after you subscribe to join, and enhance your investment knowledge and community. The Financial Information and Financial Content provided by Marketgainer.com is for informational purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or endorsement, recommendations, or sponsorship of any company or security by Marketgainer.com. You acknowledge and agree that any request for information is unsolicited and shall neither constitute nor be construed as investment advice by Marketgainer.com to you. It is strongly recommended that you seek outside advice from a qualified securities professional prior to making any securities investment. Marketgainer.com does not provide or guarantee any legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or informational source. All material herein was prepared by based upon information believed to be reliable. The information contained herein is not guaranteed by Market Gainer to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Market Gainer is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com. (C)1994-2006 M2 COMMUNICATIONS LTD |
| TheRumpledOne 6,411 posts msg #42779 - Ignore TheRumpledOne |
4/6/2006 2:17:39 PM bellwetherreport.com: Bellwether Report Issues Alert on Generex Biotechnology Corp. via COMTEX April 6, 2006 Apr 06, 2006 (M2 PRESSWIRE via COMTEX News Network) -- The Bellwether Report Takes Notice Of Generex Biotechnology Corp. (Nasdaq:GNBT) Generex Biotechnology knows that needles can be a real pain for diabetics, so the firm created the RapidMist drug delivery system that mists its Oral-lyn insulin into their mouth, where it is absorbed. The firm is also working on delivery systems for vaccines, growth and other hormones, and monoclonal antibodies. Generex is seeking partners to help fund its research and development activities. Subsidiary Antigen Express is developing immunotherapies for various diseases, including SARS, HIV, cancer, smallpox, and type I diabetes. Generex ended its joint venture with Elan to develop drug delivery technologies for prostate cancer, endometriosis treatments, and pain. Early morning trading saw stock rise 5% following a recent announcement that there is a continual global demand supporting development of avian flu treatments and antiviral drugs. On April 3, 2006, Dr. Carlton Turner, President and CEO of Carrington Laboratories, gave an overview on the market, commenting that, "Policymakers from around the world are responding as best they can to the threat of an H5 Avian Flu pandemic. The challenge lies in trying to find the right antigen, producing enough of it to protect the world's population and then finding a way to deliver it to large populations efficiently." Vice President of Generex and President of Antigen Express, Dr. Eric Vonhofe, expressed great confidence in their product, explaining that," Last fall, the government paid about $100 million for an egg-based vaccine, but that will probably be enough for only about 3 million people. In contrast, our vaccine which is synthetic can be made on a 100 kg scale quickly, efficiently and at a relatively inexpensive rate." However, antiviral drugs currently being stockpiled as part of a global strategy to treat Avian Flu may have little therapeutic value once the deadly cytokine store has been triggered. As explained by James A. Joyce, Chairman and CEO at Aethlon Medican Inc. (OTC BB:AEMD) "Once a cytokine storm has been triggered, the Hemopurifier could serve as the first, and perhaps only option for treating H5N1 infected patients....." The BWR Research Team will continue to follow the market sentiment on this company and numerous others. To review research on Blue Dolphin Energy, as well as many more exciting articles we encourage you to visit www.bellwetherreport.com. You can find these reports under the "Today's Articles" section. No credit Card Needed!! The Bellwether Report will continue to research the small cap markets to bring you exciting opportunities!! If you are interested in receiving more information on these small cap opportunities and other features of our site, feel free to sign up for a complimentary subscription to the #1 online investment tool www.bellwetherreport.com. All material herein was prepared by the Bellwetherreport.com, (Bellwether) based upon information believed to be reliable. The information contained herein is not guaranteed by Bellwether to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bellwether is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Bellwether may receive compensation in cash or shares from independent third parties or from the companies mentioned. Bellwether's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Bellwether will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Bellwether undertakes no obligation to update such statements. M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com. (C)1994-2006 M2 COMMUNICATIONS LTD |
| TheRumpledOne 6,411 posts msg #42780 - Ignore TheRumpledOne |
4/6/2006 2:18:11 PM TheSUBWAY.com Posts Stock Pick List: Critical Component for Maximizing Shareholder Value! via COMTEX April 6, 2006 NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Peter Antipatis of Capital Research Group Inc. WESTON, FL, Apr 06, 2006 (MARKET WIRE via COMTEX News Network) -- TheSUBWAY.com names the following stocks to its Stock Pick List: eWAN1, Inc. (OTC: EWAN), Generex Biotechnology Corporation (NASDAQ: GNBT), Napster (NASDAQ: NAPS), SIRIUS Satellite Radio (NASDAQ: SIRI). eWAN1, Inc. (OTC: EWAN) announced today that St. Petersburg, Florida-based Spartan Securities Group, Ltd. has assisted eWAN in composing an Information and Disclosure Statement that will be filed with Pinksheets.com, pursuant to Rule 15C2-11 of the SEC Securities and Exchange Act of 1934, in order to move the Company from "Unsolicited" Pink Sheet listing status to "Fully Compliant" listing Status. The status upgrade will require final NASD approval. Other stocks highlighted include Generex Biotechnology Corporation (NASDAQ: GNBT): Stock Pick List, down 1% on 3 million shares, Napster (NASDAQ: NAPS): Stock Pick List, up 1% on 2 million shares, SIRIUS Satellite Radio (NASDAQ: SIRI): Stock Pick List, up 1% on 3 million shares. "Stocks have been hard-pressed to pick a direction in trading lately, going on a tear for a few days, only to see those gains wane in the next several sessions. The Dow Jones Industrial Average is, in fact, only recently beginning to move off the levels it was at when the Federal Reserve began raising rates a year ago." More is available at: http://www.thesubway.com. TheSUBWAY.com's Daily Stock Updates: TheSUBWAY.com, a leader in corporate communications and finance, highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions. The aforementioned commentary is not meant to be indicative of a "long term" view of any of the companies listed. For more go to http://www.thesubway.com. All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRG has been compensated one million five hundred thousand shares for EWAN. CRG has received two million shares in past compensation and those shares have been sold to date. CRG intends to sell its shares. CRG has sold approximately zero EWAN shares to date. CRG may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRG's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. CONTACT: Charles T. Tamburello Capital Research Group Inc 954-217-9555 SOURCE: TheSUBWAY.com Copyright 2006 Market Wire, All rights reserved. |
| EWZuber 1,373 posts msg #42783 - Ignore EWZuber |
4/6/2006 4:43:39 PM ANY biotech stock is highly speculative and can lose 50% overnight on any news from the FDA or from adverse reactions when tested on the general population. I always advocate put options on biotech's as a downside protection but this one is not optionable. I would caution to use only money that is disposable. Technically the stock is in a consolidation pattern on the Weekly Chart. If it closes the Week significantly below ~ $2.80 it will enter distribution. Only support here on the Weekly Chart is at the 10 WK.MA (at ~$2.28) which is typically rather weak as support. Todays EoD chart created a tentative buy signal but buying on a gap is dangerous. Hourly Chart held up ok and I think this is the longest time frame where I would make the decision so as to avoid a potential large loss. A buy signal on the hourly chart is looming at todays close so I would wait to see what tomorrow brings. It will print the important Weekly Chart candlestick as well. JMHO |
| TheRumpledOne 6,411 posts msg #42874 - Ignore TheRumpledOne |
4/10/2006 2:48:31 PM marketgainer.com: Market Gainer Reports On Generex Biotechnology Corp. via COMTEX April 10, 2006 Apr 10, 2006 (M2 PRESSWIRE via COMTEX News Network) -- Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the markets. Generex Biotechnology Corp. (NASDAQ:GNBT), has gotten the attention of our research team this morning. Our goal is to create a community of international investors who consistently and effectively capitalize on the enormous gains that the small-cap Canadian and American exchanges offer. Generex Biotechnology Corp. (NASDAQ:GNBT), a leader in the area of buccal drug delivery and developer of Generex Oral-lyn, the Company's proprietary oral insulin spray product, announced interim three-month results of a long-term six-month clinical trial performed in 24 adolescents and 5 young adult patients with Type-1 diabetes mellitus (DM). This data continuously showed that replacing just 1 one daily subcutaneous injection (s.c.) of regular insulin with Generex Oral-lyn during the day, improves parameters of metabolic control in the same manner observed with intensively monitored standard therapy. At the 3rd month evaluation of this six-month trial, it was demonstrated that a trend similar towards normalization exists when replacing the lunch-time dose of regular insulin with the Generex Oral-lyn spray. In fact, not only Daily Glucose Profiles and Fructosamine demonstrated improved values but, of special importance, Glycosylated Hemoglobin (HbA1c), the criterion standard to evaluate metabolic control in Diabetes, showed a significant improvement when compared to standard therapy. The investigators concluded, in their three-month interim analysis, that successful and efficient replacement of injected regular insulin at lunchtime was achieved with Generex Oral-lyn altogether with 100% compliance. These encouraging results prompted the investigators and the partners Generex-Pharmabrand to design studies using larger number of Type-1 DM subjects and replacing the three mealtime doses of regular insulin with the Generex-Oral-lyn spray on subjects maintained in once daily glargine insulin therapy. These larger studies will be designed for approval in Canada and other countries. Marketing Program sponsored by the Consortium Generex-Pharmabrand.- The above mentioned data was presented and discussed in a seminar that included a marketing program. It was held by the Company's Joint Venture partner, PharmaBrand SA. All three-month results in safety and efficacy were discussed in Quito, Ecuador by Dr. Jaime Guevara-Aguirre M.D. during a meeting of 150 doctors (Pharmabrand sponsored this meeting as part of its post-approval marketing program). The results were received with enthusiasm by the doctors who will make use of them when Generex Oral-lyn is marketed and distributed nationwide in the next few weeks. A week-long training seminar concluded Thursday, April 6, 2006, for the PharmaBrand S.A. sales force, which is preparing to begin nationwide marketing of the first commercial run of Generex Oral-lyn produced in Ecuador. The April 2006 issue of Pediatrics features a study on the prevalence and correlation of depressed mood in adolescents with diabetes, entitled, "Prevalence and Correlates of Depressed Mood Among Youth with Diabetes." The results of the study showed an association between higher mean HbA1c and frequency in emergency room visits, and depressed mood. "The Pediatrics study demonstrates the vicious cycle created by a breakdown of therapy, increased complications leading to depressed moods in adolescents. Dr. Guevara-Aguirre's results shows that patient friendly Generex Oral-lyn leads to continuous compliance in adolescents," said Anna Gluskin, Generex's President & Chief Executive Officer. Following this announcement, shares of Generex Biotechnology Corp. were on the rise this morning. Share price is up 7% on more than their average volume. M.G will continue doing research on Generex Biotechnology Corp. (NASDAQ:GNBT), both short term and long term, and invite any shareholders to our site, where you can partake in communicating with other investors on the company. The information provided is brief and informative however becoming a member to our site will give you access to all the on-going information we come across on the above mentioned company. Investors seeking a resource to further their investment knowledge and be informed of exciting opportunity should take the easy step of becoming a member to www.marketgainer.com. Our service is free and at no time will we ever push any sort of annual subscription on you. The Market Gainer motto is "Our Success depends on Yours!" This information has been brought to your attention by the research team at www.marketgainer.com and comes from an unbiased perspective. Although we are a boutique research firm, we have not made any investments in the above mentioned companies. The Financial Information and Financial Content provided by Marketgainer.com is for informational purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or endorsement, recommendations, or sponsorship of any company or security by Marketgainer.com. You acknowledge and agree that any request for information is unsolicited and shall neither constitute nor be construed as investment advice by Marketgainer.com to you. It is strongly recommended that you seek outside advice from a qualified securities professional prior to making any securities investment. Marketgainer.com does not provide or guarantee any legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or informational source. M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com. (C)1994-2006 M2 COMMUNICATIONS LTD |
| StockFetcher Forums · General Discussion · What do you think of GNBT? | << 1 2 3 4 >>Post Follow-up |
Copyright 2022 - Vestyl Software L.L.C.•Terms of Service | License | Questions or comments? Contact Us
EOD Data sources: DDFPlus & CSI Data
Quotes delayed during active market hours. Delay times are at least 15 mins for NASDAQ, 20 mins for NYSE and Amex. Delayed intraday data provided by DDFPlus